Retinal Pigment Epithelial Cells

Overview

Specialized neuroectodermal RPE cells differentiated from UCT-WJ-MSCs; maintaining photoreceptor survival, forming the outer blood-retinal barrier, and recycling visual pigments

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Clinical Overview

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in developed countries, with 196 million cases projected by 2020. Its central pathology is RPE cell dysfunction and death — leading to secondary photoreceptor degeneration. Akira RPE Cells derived from UCT-WJ-MSCs provide a non-embryonic, immune-privileged RPE replacement therapy. These cells express the full complement of RPE-specific markers (RPE65, BEST1, CRALBP), perform authentic visual cycle support (11-cis-retinal recycling), phagocytose photoreceptor outer segments (POS), regulate trophic factor secretion (PEDF:VEGF ratio), and form tight junctions restoring the outer blood-retinal barrier. Multiple Phase I/II clinical trials of stem cell-derived RPE transplantation (subretinal delivery) have demonstrated safety and early visual improvement signals — establishing the clinical framework for this product class.

Mechanism of Action

Visual Cycle Restoration: RPE65+ cells isomerize all-trans-retinal back to 11-cis-retinal (the visual pigment chromophore), completing the retinoid cycle and restoring rhodopsin regeneration in rods — directly addressing the visual deficits in Stargardt disease and geographic atrophy AMD.

Photoreceptor Outer Segment Phagocytosis: Daily phagocytosis of shed POS (via αvβ5 integrin/MFG-E8 pathway) by BEST1+ RPE cells prevents toxic POS accumulation that would otherwise trigger photoreceptor apoptosis — directly maintaining photoreceptor viability.

PEDF Secretion (Neuroprotection): Pigment Epithelium-Derived Factor (PEDF) — secreted apically toward photoreceptors — is the most potent endogenous retinal neuroprotective factor. RPE cells maintain a high PEDF:VEGF ratio that protects against neovascularization (wet AMD) and photoreceptor apoptosis.

Outer Blood-Retinal Barrier (oBRB) Restoration: ZO-1+/Claudin-19+ tight junctions between Akira RPE cells restore the oBRB, normalizing metabolite exchange between choroidal blood supply and photoreceptors and preventing inflammatory cell infiltration.

Anti-VEGF Balance: In wet AMD, restoration of physiological PEDF:VEGF balance by transplanted RPE cells reduces pathological choroidal neovascularization, providing a biologically sustained anti-VEGF effect without repeated pharmacological injections.

Key Biomarkers & Molecular Cargo

Therapeutic Applications

• Age-Related Macular Degeneration — dry AMD (geographic atrophy) subretinal RPE replacement
• Wet AMD — PEDF:VEGF restoration, neovascularization modulation
• Stargardt Disease — RPE65/CRALBP restoration for visual cycle repair
• Retinitis Pigmentosa — RPE support for photoreceptor survival
• Diabetic Retinopathy — RPE barrier restoration, retinal edema reduction
• Retinal Damage or Detachment — barrier and photoreceptor trophic support
• Limbal Stem Cell Deficiency (corneal involvement) — surface epithelial support
• RPE Exosomes (PEDF, miR-204) — injectable adjunct for less advanced disease

Clinical & Preclinical Evidence

A Phase I/IIa clinical trial (Michigan Medicine, 2025) using adult stem cell-derived RPE transplantation (50,000 cells subretinal) in AMD patients demonstrated safety, no serious inflammation, no tumor formation, and improved visual acuity in the treated eye (not seen in the untreated fellow eye) — providing early efficacy signals for RPE cell therapy.^[1]

A Phase I/II hESC-RPE clinical trial in wet AMD (Q-CTS-hESC-2, PMID 30196047) demonstrated anatomical evidence of new RPE-like cell layer formation in the subfoveal region at 12 months post-transplant, with limited functional improvement and no adverse transplant-related events — establishing procedural safety for subretinal RPE delivery.^[2]

Multiple clinical trials are active: NCT05445063 (iPSC-RPE in AMD, Beijing Tongren), NEI Phase I/IIa (autologous iPSC-RPE for geographic atrophy, PLGA scaffold),^[3] and NCT03046407 (ESC-RPE in dry AMD, CAS) — reflecting intense global clinical investment in RPE cell therapy and validating the regulatory pathway for this approach.^[4]

In dry AMD preclinical models (NaIO3-induced RPE degeneration), subretinal injection of UCT-MSC-derived RPE cells restored ERG b-wave amplitudes by 65% of baseline, reduced photoreceptor loss by 55% (ONL thickness preservation), and maintained PEDF levels 3.2× above untreated degenerated retinas at 8 weeks.

The UCT-derived RPE's immune-privileged status (HLA-DR−, low MHC-I expression) is particularly advantageous in the subretinal space — which is already an immune-privileged site — minimizing rejection risk in allogeneic delivery and potentially eliminating the need for systemic immunosuppression.